Novo Nordisk shares rose as much as 2.2% on August 25, 2026. JPMorgan increased its 2026 sales expectations and stock price target for the company.
Analysts cited stronger-than-expected growth for the weight-loss drug Wegovy outside the U.S. The bank also noted limited generic erosion for the diabetes treatment Ozempic.
JPMorgan raised its 2026 sales forecast for the company by 5%. The bank lifted its December 2027 price target from 250 to 275 Danish kroner.
JPMorgan maintained a Neutral rating on the stock. Deutsche Bank reiterated its Hold rating on the same day. Deutsche Bank noted declining new prescription trends for some of the company's weight-loss drugs.